Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-601 for the treatment of human immunodeficiency virus (HIV) infection; OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug; OBP-1101 (Telomescan F35), a virus for blood floating cancer cells (CTC) detection; OBP-401 (Telomescan), a virus for inflammatory disease detection, and OBP-1102, a virus for leukemia detection, among others.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

Konica Minolta Inc. is an Innovative Company and continues to create inspiring products and services in the field of imaging. An innovative corporation that continues to create inspiring products and services in the field of imaging. A global corporation that leads the market by advanced technologies and reliability. The Konica Minolta brand shows intellectual creativity with its challenging, reliable, friendly personality. Four unique characteristics help realize the ideal value of the brand: broad technical expertise covering the entire imaging field; a culture relentlessly committed to creating great products and services; unique product groups developed from integrated technologies; a marketing service network that swiftly copes with customers’ needs. The essence of their brand is Konica Minolta’s comprehensive technological expertise that yields highly original innovations, which are a constant source of surprise to customers. The logo is a representation of their brand value and company name and expresses what Konica Minolta offers to customers. The Konica Minolta Group owns a wide array of specialized technologies and technologies that support the competitiveness and attractiveness of their products. These technologies are defined as our core technologies, totaling twelve – four in materials, two in optics, two in nano-fabrication and four in imaging fields. Throughout their history, they have expanded and advanced these technologies, integrating them at whole new levels so that they are the driving force of our production activities. They continuously strive to integrate these technologies into innovative products with new functions and added value that contribute to the daily lives of people at home and at work. Naturally, this also includes our range of Business Solution products.

Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumor cells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan.

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.

Shanghai Shidande Biotechnology Co., Ltd., established on 2003-11-27, Business scope includes general items:Technology transfer in the field of biological expertise,technical consulting,Technical Services,technology development,Research and Development of Plant Extracts,new medical research,Pharmaceutical Intermediates(In addition to drugs)and laboratory reagents(In addition to chemical hazards)promotion of,Engaged in the import and export of goods and technology,Conference and Exhibition Services,Standardized service,business management,Information Consulting Service(Not including licensing information consulting services),Health Consulting Services(Does not include medical services),marketing planning,e-commerce(Not to engage in financial business),packaging service,food production(limited branch),food business(limited branch),Production of food additives,Sales(limited branch).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Shanghai Likang Pharmaceutical Technology Co. Ltd. is a Chinese private company located in Shanghai. The firm produces and distributes pharmaceutical drugs.

Momotaro-Gene Inc. engages in the development of molecular targeting drugs for cancer treatment. It also acting as a bridge between promising technology seeds in life science and real drug market in order to effectively bringing the research outcome to the citizens globally. The company was founded on August 17, 2007 and is headquartered in Okayama, Japan.

SonoCore, Inc. is a Japanese company located in Tokyo that engages in research and development of nano-bubbles and related medical devices. It was founded in 2014.

Wasion Biopharmaceutical (Suzhou) Co., Ltd., established on 2012-11-01, The business scope includes the production of artemisinin derivatives,Vinpocetine API,Compound Artemether Tablets and Vinpocetine Tablets,Sell ​​self-produced products(Can only be operated after receiving a license);Biotechnology R&D,Technical service and technology transfer,and related technology imports,Chemical raw materials and products(Excluding hazardous chemicals),Biological product(Hazardous Chemicals,Except for drugs that need to be approved)Wholesale and import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:pharmaceutical production;Pharmaceutical commissioned production;Drug import and export;Import and export;Technology Import and Export;Import and export agency;Production of Class II Medical Devices;Production of medical masks;Production of protective equipment for medical personnel(Class II medical device)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Chemical product production(No licensed chemical products);Chemical product sales(No licensed chemical products);Manufacturing of daily chemical products;Sales of daily chemical products;Cosmetics Wholesale;Cosmetics Retail;Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Food Additive Sales;Sales of Class II Medical Devices;Wholesale medical masks;Medical Mask Retail;daily mask(non-medical)Production;daily mask(non-medical)Sales;Production of labor protection products;Sales of labor protection products;Wholesale of protective equipment for medical staff;Retailing of protective equipment for healthcare workers(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

SurExam Bio-Tech Co., Ltd. provides personalized medical system solutions focused on tumor molecular diagnostic products and clinical medicine testing services. Its products include medical kits, as well as it provides medical testing services. The company was founded on November 28, 2006 and is headquartered in Guangzhou, China.

Jinan Liangfu Jinghe Pharmaceutical Technology Co., Ltd., established on 2009-01-16, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Import and export;Technology Import and Export;Class III Medical Device Leasing;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices;Biochemical product technology research and development;Chemical product sales(No licensed chemical products);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals);New material technology research and development;Class II Medical Device Leasing;Medical Research and Experimental Development;Conference and Exhibition Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd., part of Jiangxi Jemincare Group Co., Ltd., is a Chinese company. The firm develops, manufactures and sells pharmaceutical products.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

The Nanjing General Hospital of People's Liberation Army (NGH; Chinese: 中国人民解放军南京总医院), formerly Nanjing General Hospital of Nanjing Military Command (Chinese: 中国人民解放军南京军区南京总医院), or Nanjing General Hospital, The Military General Hospital, is also known as Jinling Hospital (formally Jinling Hospital of the Medical School of Nanjing University) which used to be Central Hospital. NGH is located at 305 Zhongshan East Road, Nanjing, Jiangsu Province, China. It is a large comprehensive teaching hospital integrating medical services with teaching and research.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.